Bladder transitional cell carcinoma
Not recruitingStudy of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall
Study of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall
- Disease:Bladder transitional cell carcinoma
- Substances:Bacillus Calmette-Guérin (Bcg), TiceNogapendekin alfa inbakicept
Germany- Participants:18–64 years · 65+ years
- Substances:Bacillus Calmette-Guérin (Bcg), Tice
- Sponsor:Immunitybio Inc.











